Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
No reason for the revision to the earnings forecast was provided. The forecast assumes an exchange rate of ¥155.00/USD and a naphtha price of ¥92,000/KL, and incorporates to a certain extent the impact of the situation in the Middle East.
Impairment losses: ¥34,607 million; business structure improvement expenses: ¥26,627 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥2,360,000 million |
| Operating profit | Not disclosed → ¥177,000 million |
| Profit attributable to owners of the parent | Not disclosed → ¥70,000 million |
| Net income per share | Not disclosed → 42.4 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Results for the fiscal year ended March 2026: revenue of ¥2,328,515 million, operating profit of ¥151,744 million, profit attributable to owners of the parent of ¥60,947 million, and basic earnings per share of ¥37.16 |
| Reason for the revision | No reason for the revision to the earnings forecast was provided. The forecast assumes an exchange rate of ¥155.00/USD and a naphtha price of ¥92,000/KL, and incorporates to a certain extent the impact of the situation in the Middle East. |
| Details and amount of extraordinary loss | Impairment losses: ¥34,607 million; business structure improvement expenses: ¥26,627 million |
| Dividend forecast revision | For the fiscal year ending March 2027, the company plans an interim dividend of ¥8, a year-end dividend of ¥8, and an annual dividend of ¥16. There is no statement that this constitutes a revision to the dividend forecast. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Factors cited for the results for the fiscal year included lower shipments following business withdrawals and transfers, price competition for products, foreign exchange movements, improved terms of trade, increased sales of pharmaceuticals in North America, and sales milestone income. The forecast for the fiscal year ending March 2027 assumes an exchange rate of ¥155.00/USD and a naphtha price of ¥92,000/KL, and incorporates to a certain extent the impact of the situation in the Middle East on raw material prices and the supply chain.